Bafna Pharmaceuticals Limited (NSE:BAFNAPH)
India · Delayed Price · Currency is INR 301.45
-6.15 (-2.00%)
Sep 11, 2026, 3:15 PM IST
Bafna Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,426 | 1,506 | 1,459 | 1,525 | 1,153 | 851.4 |
| 1,426 | 1,506 | 1,459 | 1,525 | 1,153 | 851.4 | |
Revenue Growth | -3.14% | 3.26% | -4.33% | 32.18% | 35.48% | 19.55% |
Cost of Revenue | 975.64 | 1,028 | 1,034 | 1,073 | 770.12 | 515.41 |
Gross Profit | 450.12 | 478.66 | 424.19 | 452.15 | 383.38 | 336 |
Selling, General & Admin | 218.95 | 235.51 | 216.04 | 198.38 | 166.34 | 149.37 |
Other Operating Expenses | 113.56 | 76.77 | 89.57 | 129.71 | 42.94 | 65.29 |
Operating Expenses | 397.35 | 373.01 | 354.69 | 378.79 | 265.66 | 269.59 |
Operating Income | 52.77 | 105.65 | 69.49 | 73.36 | 117.72 | 66.41 |
Interest Expense | -36.93 | -35 | -25.62 | -19.38 | -17.98 | -5.24 |
Interest & Investment Income | - | 0.68 | 1.36 | 1.25 | 0.45 | 0.34 |
Currency Exchange Gain (Loss) | - | 37.06 | 13.44 | 16.72 | 14.77 | 3.61 |
Other Non Operating Income (Expenses) | 60.72 | 1.3 | 2.72 | 0.86 | -2.3 | 8.5 |
EBT Excluding Unusual Items | 76.56 | 109.7 | 61.4 | 72.82 | 112.67 | 73.62 |
Gain (Loss) on Sale of Assets | - | 0.01 | -0.74 | 0.66 | 1.96 | - |
Asset Writedown | - | - | -21.46 | - | - | - |
Other Unusual Items | - | - | - | - | - | -21.57 |
Pretax Income | 76.56 | 109.7 | 41.53 | 73.48 | 116.16 | 52.16 |
Income Tax Expense | -1.3 | -1.3 | - | - | 2.78 | - |
Earnings From Continuing Operations | 77.86 | 111 | 41.53 | 73.48 | 113.38 | 52.16 |
Net Income to Company | 77.86 | 111 | 41.53 | 73.48 | 113.38 | 52.16 |
Net Income | 77.86 | 111 | 41.53 | 73.48 | 113.38 | 52.16 |
Net Income to Common | 77.86 | 111 | 41.53 | 73.48 | 113.38 | 52.16 |
Net Income Growth | -5.81% | 167.30% | -43.49% | -35.19% | 117.36% | -10.48% |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | 24 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | 24 |
Shares Change | 1.32% | - | - | - | - | -0.13% |
EPS (Basic) | 3.24 | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 |
EPS (Diluted) | 3.24 | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 |
EPS Growth | -7.03% | 167.18% | -43.49% | -35.15% | 117.23% | -10.36% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -95.32 | 2.76 | -60.93 | -17.66 | 21.87 |
Free Cash Flow Per Share | - | -4.03 | 0.12 | -2.58 | -0.75 | 0.93 |
Gross Margin | 31.57% | 31.78% | 29.08% | 29.66% | 33.24% | 39.46% |
Operating Margin | 3.70% | 7.02% | 4.76% | 4.81% | 10.21% | 7.80% |
Profit Margin | 5.46% | 7.37% | 2.85% | 4.82% | 9.83% | 6.13% |
Free Cash Flow Margin | - | -6.33% | 0.19% | -4.00% | -1.53% | 2.57% |
EBITDA | 116.46 | 166.38 | 118.39 | 123.32 | 171.07 | 121.34 |
EBITDA Margin | 8.17% | 11.05% | 8.12% | 8.09% | 14.83% | 14.25% |
D&A For EBITDA | 63.68 | 60.73 | 48.9 | 49.95 | 53.34 | 54.93 |
EBIT | 52.77 | 105.65 | 69.49 | 73.36 | 117.72 | 66.41 |
EBIT Margin | 3.70% | 7.02% | 4.76% | 4.81% | 10.21% | 7.80% |
Effective Tax Rate | - | - | - | - | 2.40% | - |
Revenue as Reported | 1,486 | 1,554 | 1,486 | 1,560 | 1,186 | 868.38 |
Advertising Expenses | - | 8.09 | 3.49 | 4.72 | 3.66 | 0.96 |